GKOS Company Profile and Key Details

Q: Who are the executives of GKOS?

Dr. Mory Gharib Ph.D.Co-FounderMr. David S. HaffnerSenior Vice President of New TechnologiesMs. Michele M. AllegrettoSenior Vice President of HRMs. Jane E. RadySenior Vice President of Corporation Strategy & Bus. Devel.Mr. Thomas William BurnsChairman & Chief Executive OfficerMr. Joseph E. GilliamPres & Chief Operating OfficerMr. Alex R. ThurmanSenior Vice President & Chief Financial OfficerMr. Chris M. CalcaterraExecutive Vice President of Global Commercial OperationsDr. Tomas Navratil Ph.D.Chief Devel. OfficerMr. Christopher William LewisVice President of Investor Relations & Corporation AffairsMs. Diane W. BiagiantiSenior Vice President & Gen. CounselMs. Diana A. SchererVice President of Compliance & Deputy Gen. Counsel

NYSE : GKOS

Glaukos

$170.38

-9.41-5.23%

At Close 4:00 PM

59.46

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Glaukos Corporation (GKOS) stock declined over -5.23%, trading at $170.38 on NYSE, down from the previous close of $179.79. The stock opened at $176.71, fluctuating between $169.61 and $179.96 in the recent session.

Stock Snapshot

179.79

Prev. Close

10.05B

Market Cap

169.61

Day Low

-198.12

P/E Ratio

-0.86

EPS (TTM)

-1.6

Cash Flow per Share

176.71

Open

58.98M

Number of Shares

179.96

Day High

96.61%

Free Float in %

9.45

Book Value

1.01M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	176.50	179.96	169.26	170.38	1.01M
Sep 09, 2026	183.15	183.33	178.52	179.79	587.92K
Sep 08, 2026	175.55	185.35	172.98	185.04	1.16M
Sep 04, 2026	177.80	181.52	175.14	177.47	572.52K
Sep 03, 2026	180.80	181.30	178.72	180.35	610.18K
Sep 02, 2026	176.87	182.28	176.35	179.53	768.69K
Sep 01, 2026	179.97	180.14	175.33	176.70	507.23K
Aug 31, 2026	178.67	180.08	174.28	179.56	455.47K
Aug 28, 2026	181.10	182.23	177.77	179.87	551.89K
Aug 27, 2026	178.51	183.32	178.43	181.91	442.29K
Aug 26, 2026	180.11	181.89	176.82	180.57	504.03K
Aug 25, 2026	186.21	187.14	179.20	181.39	639.62K
Aug 24, 2026	184.13	186.88	181.75	185.65	622.28K
Aug 21, 2026	185.00	187.60	183.68	184.89	439.99K
Aug 20, 2026	187.73	191.62	183.25	184.89	791.86K
Aug 19, 2026	186.00	190.06	185.96	189.55	505.12K
Aug 18, 2026	185.00	186.66	175.04	184.15	625.59K
Aug 17, 2026	183.55	186.03	181.84	185.62	725.11K
Aug 14, 2026	189.89	190.00	184.22	184.53	738.67K
Aug 13, 2026	187.00	189.69	185.82	189.45	762.13K

Contact Details

Aliso Viejo, CA 92656

United States

https://www.glaukos.com 949 367 9600

About Company

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Stock Peers

BIO

-3.15-0.83%

Bio-Rad Laboratories, Inc.$376.97 BIO-B

21.98+6.02%

Bio-Rad Laboratories, Inc.$365.08 PEN

0.31+0.10%

Penumbra, Inc.$319.57 SYK

-1.04-0.38%

Stryker Corporation$275.39 ITGR

-0.34-0.27%

Integer Holdings Corporation$125.86 ABT

-0.27-0.26%

Abbott Laboratories$105.25 HAE

0.32+0.31%

Haemonetics Corporation$103.16 ZBH

0.39+0.41%

Zimmer Biomet Holdings, Inc.$94.61 MDT

-0.5-0.54%

Medtronic plc$91.89 EW

-0.54-0.62%

Edwards Lifesciences Corporation$86.18

Company Overview

Glaukos Corporation (NYSE:GKOS) closed at $170.06 USD, losing -$9.73 (-5.41%) from the previous close of $179.79. The stock is currently mid-range between its 52-week high and low $73.16 and $191.62. With a market capitalization of about $10.03 billion, Glaukos Corporation is classified as a large-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 800.54 thousand shares, in line with its 52-week average. Headquartered in Aliso Viejo, CA, Glaukos Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Thomas William Burns, the company employs approximately 1,094 people and listed since June 25, 2015. Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases.

Technical Performance

GKOS has shown sold momentum, gaining 11.31% over the past week and 41.62% over the past quarter, though year-to-date performance is up 9.33%. Short-term trend indicators are mixed aligned (SMA20 4.99%, SMA50 4.93%, SMA200 23.37%). The stock’s 14-day RSI is 57.38 (neutral), while the ATR of 5.22 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -6.76% below its high and over 65.98% above its low. Average 10-day trading volume of 665.73 thousand shares is below the 3-month average of 810.28 thousand, indicating normal recent market interest.

Valuation Metrics

Glaukos Corporation trades at a P/E ratio of -53.43, slightly below the S&P 500 average, with a price-to-sales ratio of 16.71 and a price-to-book ratio of 14.86 reflecting a rich premium to book value. The P/FCF stands at -839.85, also below market averages. Compared to sector medians, Glaukos Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Glaukos Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$43.59. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Glaukos Corporation generated EPS of -$3.27 over the past year. Five-year average earnings growth is -3.95%. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.27. Next year's EPS is expected at $11.28. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 37 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $215.00 to $103.00. The high target offers 19.58% upside. The low target suggests -42.71% downside. The mean target is $147.14. This offers -18.16% upside. Glaukos Corporation earnings surprise history is a mixed track record. The quarter that ended July 29, 2026, missed forecasts by -33.5%. The prior quarter beat by -40.0%. Over the last six quarters, Apple has recorded several small beats. These include -33.33% in April 30, 2025.

Frequently Asked Questions

What is the current Glaukos Corporation (GKOS) stock price?

Glaukos Corporation (NYSE: GKOS) stock price is $170.38 in the last trading session. During the trading session, GKOS stock reached the peak price of $179.96 while $169.61 was the lowest point it dropped to. The percentage change in GKOS stock occurred in the recent session was -5.23% while the dollar amount for the price change in GKOS stock was - $9.41.

GKOS's industry and sector of operation?

The NYSE listed GKOS is part of Medical - Devices industry that operates in the broader Healthcare sector. Glaukos Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GKOS?

Dr. Mory Gharib Ph.D.
Co-Founder
Mr. David S. Haffner
Senior Vice President of New Technologies
Ms. Michele M. Allegretto
Senior Vice President of HR
Ms. Jane E. Rady
Senior Vice President of Corporation Strategy & Bus. Devel.
Mr. Thomas William Burns
Chairman & Chief Executive Officer
Mr. Joseph E. Gilliam
Pres & Chief Operating Officer
Mr. Alex R. Thurman
Senior Vice President & Chief Financial Officer
Mr. Chris M. Calcaterra
Executive Vice President of Global Commercial Operations
Dr. Tomas Navratil Ph.D.
Chief Devel. Officer
Mr. Christopher William Lewis
Vice President of Investor Relations & Corporation Affairs
Ms. Diane W. Biagianti
Senior Vice President & Gen. Counsel
Ms. Diana A. Scherer
Vice President of Compliance & Deputy Gen. Counsel

How GKOS did perform over past 52-week?

GKOS's closing price is 132.89% higher than its 52-week low of $73.16 where as its distance from 52-week high of $191.62 is -11.08%.

How many employees does GKOS have?

Number of GKOS employees currently stands at 1,094.

Link for GKOS official website?

Official Website of GKOS is: https://www.glaukos.com

How do I contact GKOS?

GKOS could be contacted at phone 949 367 9600 and can also be accessed through its website. GKOS operates from One Glaukos Way, Aliso Viejo, CA 92656, United States.

How many shares of GKOS are traded daily?

GKOS stock volume for the day was 1.01M shares. The average number of GKOS shares traded daily for last 3 months was 800.54K.

What is the market cap of GKOS currently?

The market value of GKOS currently stands at $10.05B with its latest stock price at $170.38 and 58.98M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

179.79

Prev. Close

10.05B

Market Cap

169.61

Day Low

-198.12

P/E Ratio

-0.86

EPS (TTM)

-1.6

Cash Flow per Share

176.71

Open

58.98M

Number of Shares

179.96

Day High

96.61%

Free Float in %

9.45

Book Value

1.01M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	176.50	179.96	169.26	170.38	1.01M
Sep 09, 2026	183.15	183.33	178.52	179.79	587.92K
Sep 08, 2026	175.55	185.35	172.98	185.04	1.16M
Sep 04, 2026	177.80	181.52	175.14	177.47	572.52K
Sep 03, 2026	180.80	181.30	178.72	180.35	610.18K
Sep 02, 2026	176.87	182.28	176.35	179.53	768.69K
Sep 01, 2026	179.97	180.14	175.33	176.70	507.23K
Aug 31, 2026	178.67	180.08	174.28	179.56	455.47K
Aug 28, 2026	181.10	182.23	177.77	179.87	551.89K
Aug 27, 2026	178.51	183.32	178.43	181.91	442.29K
Aug 26, 2026	180.11	181.89	176.82	180.57	504.03K
Aug 25, 2026	186.21	187.14	179.20	181.39	639.62K
Aug 24, 2026	184.13	186.88	181.75	185.65	622.28K
Aug 21, 2026	185.00	187.60	183.68	184.89	439.99K
Aug 20, 2026	187.73	191.62	183.25	184.89	791.86K
Aug 19, 2026	186.00	190.06	185.96	189.55	505.12K
Aug 18, 2026	185.00	186.66	175.04	184.15	625.59K
Aug 17, 2026	183.55	186.03	181.84	185.62	725.11K
Aug 14, 2026	189.89	190.00	184.22	184.53	738.67K
Aug 13, 2026	187.00	189.69	185.82	189.45	762.13K

Contact Details

Aliso Viejo, CA 92656

United States

https://www.glaukos.com 949 367 9600

About Company

Stock Peers

BIO

-3.15-0.83%

Bio-Rad Laboratories, Inc.$376.97 BIO-B

21.98+6.02%

Bio-Rad Laboratories, Inc.$365.08 PEN

0.31+0.10%

Penumbra, Inc.$319.57 SYK

-1.04-0.38%

Stryker Corporation$275.39 ITGR

-0.34-0.27%

Integer Holdings Corporation$125.86 ABT

-0.27-0.26%

Abbott Laboratories$105.25 HAE

0.32+0.31%

Haemonetics Corporation$103.16 ZBH

0.39+0.41%

Zimmer Biomet Holdings, Inc.$94.61 MDT

-0.5-0.54%

Medtronic plc$91.89 EW

-0.54-0.62%

Edwards Lifesciences Corporation$86.18

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Glaukos Corporation has 58.98 million shares outstanding. The public float is 56.81 million shares, elevated short interest at 8.11% of float. This equals 3.95 million shares. The short ratio is 4.59 days. Institutional investors hold 106.57% of the float. Insiders own 3.62%. Calcaterra Chris M. holds 211.02 thousand shares, Burns Thomas William has 153.78 thousand shares and Navratil Tomas has 73.89 thousand shares. Over the past six months, insider transactions show net selling. They sold 133.56 thousand shares across 20 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Glaukos generated $314.71M in revenue, or $6.50 per share. Gross margin was 75.99%, operating margin -40.89%, and net profit margin -42.79%. Returns are negative, with ROA at -14.32% and ROE at -29.16%.
On valuation metrics, Glaukos trades at a P/E of -53.43, P/S of 16.71 and P/B of 14.86. The current ratio is 5.04 and quick ratio is 4.46. Operationally, the company’s inventory turnover is 2.16 and cash conversion cycle is 197.30 days. Debt-to-equity is 0.15, supported by a cash flow-to-debt ratio of -0.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Glaukos posted revenue of $314.71M, down slightly from $282.86M in the prior quarter. Gross profit was $239.14M (margin 75.99%). Operating income was - $128.70M (margin -40.9%). Net income was- $134.66M (EPS - $2.78).
The company ended the quarter with $295.43M in cash and short-term investments, a total debt of $383.74M, and net debt of $290.27M. Total assets were $940.41M, with equity of $461.77M. Financials further reflected weakness, with operating cash flow of - $57.76M, free cash flow of - $78.01M, and capital expenditures of - $20.25M.

Price Forecast & Outlook

Our AI price prediction model suggests that Glaukos Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.67%, with price expected at $176.79 by September 23, 2026, within a range of $171.91 to $181.37 3-Month Outlook: Projected rise of 102.37%, reaching $363.85 by December 08, 2026, with a range of $358.12 to $372.85. 1-Year Outlook: Projected gain of 9.86%, with price at $197.51 by September 09, 2027, within a range of $189.42 to $207.48.

Key Takeaways

Glaukos Corporation (NYSE:GKOS) shares are flat 9.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Glaukos Corporation trading at a premium to the broader market with a P/E of -53.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $121.01, suggesting -32.69% downside. Our AI forecast model points to short-term weakness (-1.67% over two weeks), a medium-term rise (102.37% over three months), and a longer-term gain (9.86% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Glaukos Corporation (GKOS) stock price?

GKOS's industry and sector of operation?

Who are the executives of GKOS?

How GKOS did perform over past 52-week?

GKOS's closing price is 132.89% higher than its 52-week low of $73.16 where as its distance from 52-week high of $191.62 is -11.08%.

How many employees does GKOS have?

Number of GKOS employees currently stands at 1,094.

Link for GKOS official website?

Official Website of GKOS is: https://www.glaukos.com

How do I contact GKOS?

GKOS could be contacted at phone 949 367 9600 and can also be accessed through its website. GKOS operates from One Glaukos Way, Aliso Viejo, CA 92656, United States.

How many shares of GKOS are traded daily?

GKOS stock volume for the day was 1.01M shares. The average number of GKOS shares traded daily for last 3 months was 800.54K.

What is the market cap of GKOS currently?

The market value of GKOS currently stands at $10.05B with its latest stock price at $170.38 and 58.98M of its shares outstanding.

Employees	1094
Beta	0.76
Sales or Revenue	$314.71M
5Y Sales Change%	0.255%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

Employees	1094
Beta	0.76
Sales or Revenue	$314.71M
5Y Sales Change%	0.255%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

GKOS Company Profile and Key Details

Glaukos

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights